Beyond Meat's IPO leads to a rare 2000-style stock surge

Beyond Meat Inc.’s first day of trading after its initial public offering brought the kind of stock surge that has been relatively rare since 2000, the year that an Internet-driven bull market ended. The producer of vegan beef and sausage substitutes soared 163 percent in its debut. Beyond Meat is only the eighth U.S. company in the past 18 years to climb at least 125 percent after completing an initial public offering of $100 million or more, according to data compiled by Bloomberg. The rest are shown in the chart. There were 29 in 2000 alone.

 

Seres Therapeutics (MCRB) began trading on the NASDAQ on 26 June 2015

No Profit, No Sales, No Prob

• Seres is developing a class of biological drugs to treat metabolic, inflammatory and infectious diseases. Among its leading candidates is SER-109, a treatment for large-intestine inflammation.
• As is typical of biotech companies that come public, Seres has no revenue or profit. Also typical, investors are betting that its therapies under development will produce blockbuster sales.

Seres Therapeutics, Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a range of biological drugs, Ecobiotic microbiome therapeutics. It is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome in the human body. Its products include SER-109, which is designed to prevent further recurrences of Clostridium difficile infection, (CDI), a debilitating infection of the colon; SER-109; SER-262, and SER-155. It's SER-262 is a multi-strain Ecobiotic microbiome therapeutic to be used following antibiotic treatment of primary CDI to prevent an initial recurrence of CDI. The Company is developing SER-287 to treat ulcerative colitis. It is developing SER-155, which is an Ecobiotic microbiome therapeutic to treat enteric pathogens.

Address

215 First Street, Suite 440
CAMBRIDGE, MA 2142
United States

Website 

http://serestherapeutics.com/